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Abstract
Background: Israel reports the world’s highest IVF cycles per capita. However, clinical outcome data of these
treatments are scarce. In a previous publication, we summarized IVF results among Maccabi Healthcare Services
members for the years 2007-2010. The main findings included an increase in mean patients’ age over the period
studied, a 50 % increase in cycle numbers during this time, and a decrease in success rate (live birth) from 18.8 % in
2007 to 14.8 % in 2010. The purpose of the current publication is to summarize IVF outcome for the years 2011-2014,
and to explore possible changes in the trends we reported previously.
Methods: IVF and live births data were collected from Maccabi Healthcare Services’ fertility treatments registry.
Analyses were conducted by treatment year and patients’ age at the initiation of treatment cycles. Autologous cycles,
were included (ovum donation cycles and frozen-thaw cycles were excluded). A successful cycle was defined if a live
birth was recorded within 10 months of its initiation.
Results: In accordance with previous data for the years 2007-2010, mean patients’ age continued to rise (from 36.2 in
2011 to 37.1 in 2014). In contrast to previous years, during which a continued increase in treatment cycles was
recorded, we found that treatment number decreased from a peak of 9,751 in 2011 to 8,623 in 2014. Contrary to
that trend, the number of patients over 40 years of age increased from 3,204 in 2011 to 3,648 in 2014. Success rate
fluctuated between 14.4 % in 2014 to 16.4 % in 2013. The majority (78 %) of treatment cycles were conducted in
four private medical centers.
Conclusions: The decrease in treatment cycles in recent years notwithstanding, Israel is still leading the world
with IVF treatments relative to population. Success rate is relatively low compared to international data. Given the
steady increase in patients’ mean age, and particularly, the increase in patients over 40 years of age, we maintain
that the low success rate reflects a growing number of treatments that a priori have a low chance of success.
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Background
The number of IVF cycles performed in Israel (relative
to population size) is the highest in the world [1]. The
main reason is the unprecedented Israeli IVF health bas-
ket, which provides practically unlimited IVF treatments
to eligible infertility patients who are under 45 years old
and have no more than two children, including single
mothers [2]. While this policy was challenged by profes-
sional organizations, it seems that for many years politi-
cians were reluctant to limit IVF treatments. Moreover,
the Ministry of Health as the regulatory body stated in
2014 that given medical considerations, IVF treatment
could be regarded as first line of treatment for patients
over 39 years of age [3].. When professional consider-
ations to stop treatments before the 45 year age limit
were challenged in court [4], the judge decided in favor
of the patient, stating that the maximal age for treatment
(45) was decided based on medical considerations and
the current medical literature. Of note, the pertinent
professional body (The Israel Fertility Association)
recommended lowering the upper age limit for IVF
treatments.
The relative low “out of pocket” cost, and the high
availability of IVF services in Israel [4] contributed to
the popularity of IVF treatments. Currently, IVF services
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are available in all Israeli public medical centers (exclud-
ing Zefat, the 3 Nazareth medical centers and Eilat), in
addition to four IVF units in private medical centers
(Elisha, HMC, Assuta Tel Aviv and Assuta Rishon
LeZion).
IVF activity is monitored by a long list of national and
international organizations, most notably the Society for
Assisted Reproductive Technologies (SART) [5] and the
Centers for Disease Control and Prevention (CDC)
(http://www.cdc.gov/art/reports/) in the United States,
and the European Society for Human Reproduction and
Embryology (ESHRE) in Europe [6]. Currently, an effort
to establish an Israeli IVF registry is underway, though
periodic comprehensive reports are not yet available.
Professor Liat Lerner-Geva presented preliminary data
on clinical pregnancy rate at the 2015 annual meeting of
the Israel Fertility Association. The Ministry of Health
publishes limited retrospective annual reports [7]. Ac-
cording to these reports available from 2000 to 2013, live
birth rate per treatment cycles ranges between 14.9-
17.2 %. These results fall significantly short of the re-
ported live birth rate per treatment cycles as published
by the above registries.
Previously, we summarized IVF results among Maccabi
members for the years 2007-2010 [8]. The main findings
included an increase in mean patients’ age over the period
examined, a 50 % increase in cycle numbers during this
period, and a decrease in success rate (live birth) from
18.8 % in 2007 to 14.8 % in 2010. The purpose of the
current communication is to summarize the IVF out-
comes for the years 2011-2014, to explore possible
changes in the trends we reported previously, while deep-
ening the analysis and exploring the policy implications of
the findings.
Methods
Maccabi Healthcare Services is the second largest Health
Maintenance Organization (HMO) in Israel covering
433,711 women in fertility ages (15-45) according to the
National Insurance Institute report of November 2014
[9], or 25.7 % of the total fertility age population
(1,687,873 women).
In an attempt to gain further insight on IVF activity in
Israel, we analyzed data generated from the Maccabi
Healthcare Services fertility treatment registry. The
Table 1 Number of IVF treatments performed, number of live births achieved from these treatments, and success rate by year
(2007-2014)
Year Number of patients Number of treatments Number of live births Cycles/patient Live birth/cycle Live birth/patient
2007 4,061 6,242 1,182 1.54 18.9 % 29.1 %
2008 4,410 7,041 1,295 1.60 18.4 % 29.4 %
2009 4,867 8,336 1,356 1.71 16.3 % 27.9 %
2010 5,282 9,297 1,384 1.76 14.9 % 26.2 %
2011 5,479 9,751 1,429 1.78 14.7 % 27.9 %
2012 5,375 9,314 1,438 1.73 15.4 % 26.7 %
2013 5,360 8,455 1,386 1.58 16.4 % 25.9 %
2014 5,577 8,623 1,238 1.55 14.4 % 22.2 %
Total 40,411 67,059 10,708 1.66 16.0 % 26.5 %
Table 2 Number of IVF treatments and success rate by year











2011 15-19 4 0 0 0.0 %
20-24 226 56 24.8 2.3 %
25-29 1,086 277 25.5 11.2 %
30-34 2,104 449 21.3 21.7 %
35-39 3,082 479 15.5 31.8 %
40-45 3,204 168 5.2 33.0 %
2012 15-19 7 2 28.6 0.1 %
20-24 187 49 26.2 2.0 %
25-29 947 273 28.8 10.2 %
30-34 1,905 437 22.9 20.5 %
35-39 2,772 468 16.9 29.9 %
40-45 3,466 209 6.0 37.3 %
2013 15-19 4 0 0.0 0.0 %
20-24 188 45 23.9 2.2 %
25-29 832 235 28.2 9.9 %
30-34 1,657 452 27.3 19.7 %
35-39 2,470 425 17.2 29.3 %
40-45 3,271 228 7.0 38.8 %
2014 15-19 4 0 0.0 0.0 %
20-24 184 52 28.3 2.1 %
25-29 804 203 25.2 9.4 %
30-34 1,547 380 24.6 18.0 %
35-39 2,411 386 16.0 28.0 %
40-45 3,648 217 5.9 42.4 %
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responsible HMO reimburses all IVF treatments for
Israeli citizens (in public and private medical centers
alike); therefore, reliable information is gathered on the
number of cycles performed in all IVF units.
All IVF treatments of Maccabi members are routinely
registered as part of the reimbursement system that
serves the financial infrastructure to all treatments per-
formed. Live birth is reimbursed by the National Insurance
Institute of Israel, and therefore is not directly reported to
the pertinent HMO. However, as a default, the newborn is
registered to his/her mother’s HMO, generating a sig-
nificant financial movement for the HMO (one more
member). A cross-match between these two financial
movements (paying the medical center for IVF and add-
ing a new member to the HMO) can yield a good esti-
mate (though not perfect) of live birth rate post IVF, if a
live birth occurred within 10 months from the IVF
treatment.
In the current publication we included “fresh” cycles,
defined as ovarian stimulation + oocyte retrieval (“phase
1”) followed by fertilization and embryo transfer 2 –
6 days after oocyte retrieval (“phase 2”). We collected
data on patients’ age on the day of IVF treatment, the
specific medical center where treatment was given, and
number of cycles performed in each medical center.
Fig. 1 Age distribution of cycles by year, 2011-2014
Table 3 Mean age of IVF patients by medical center type
(public/private), 2011-2014




Table 4 Number of IVF treatments and success rates for
women ≥40 year old age group, by year (2011-204) and age






2011 Total 3,204 168 5.2
40 660 68 10.3
41 736 38 5.2
42 716 31 4.3
43 555 21 3.8
44 537 10 1.9
2012 Total 3,466 209 6.0
40 716 89 12.4
41 789 52 6.6
42 741 37 5.0
43 649 21 3.2
44 571 10 1.8
2013 Total 3,271 228 7.0
40 635 74 11.7
41 757 72 9.5
42 736 57 7.7
43 599 20 3.3
44 544 5 0.9
2014 Total 3,648 217 5.9
40 781 77 9.9
41 855 59 6.9
42 759 43 5.7
43 702 28 4.0
44 551 10 1.8
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Data for 2011-2014 were collected and summarized in
late September 2015; therefore, we assume that all preg-
nancies achieved in 2014 have ended by that time.
Results
Treatments and live birth rate
The 8 years surveyed can be divided into 2 periods: A
steady increase in the number of treatments from 2007
(6,242 treatments) to a peak in 2011 (9,751 treatments),
and a moderate decrease in treatments thereafter. Live
birth rate decreased from 18.9 % in 2007 to 14.4 % in
2014 (Table 1).
Treatments and live birth rate according to patients’ age
groups
From 2011 to 2014, a steady decrease was noted in the
treatments performed in the younger age groups (25-39),
with a parallel steady increase in the 40-45 age group. A
sharp decrease in live birth was noted for patients over
40 years of age (Table 2, Fig. 1).
Mean patients’ age
A steady increase in patients’ mean age was documented
from 2007 (35.1) to 2014 (37.1).
Mean patients’ age by type of medical center
From 2007 to 2014, 16,004 and 51,055 treatments were
performed in public and private medical centers, respect-
ively. Patients’ mean age was 35.5 and 36.5 in public and
private medical centers, respectively (Table 3).
Detailed outcome for the 40-45 age group
In all the years surveyed, a steady decrease in live birth
rate was noted from age 40 to 44. Two thousand two
Table 5 Number of IVF treatments and success rate, by year
(2011-2012) and medical center (only medical centers
with ≥100 cycles per given year were included)





2011 Total 9,751 1,429 14.7
A 914 93 10.2
B 561 40 7.1
C 673 114 16.9
D 1,958 387 19.8
E 3,908 502 12.8
F 223 49 22.0
G 120 24 20.0
H 307 48 15.6
I 161 40 24.8
J 303 18 5.9
K 170 37 21.8
2012 Total 9,314 1,438 15.4
A 889 101 11.4
B 420 44 10.5
C 637 112 17.6
D 1,988 371 18.7
E 3,574 522 14.6
F 248 42 16.9
G 109 25 22.9
H 321 48 15.0
I 152 34 22.4
J 346 37 10.7
K 189 28 14.8
aMedical center: in order to protect the confidential information, the names of
the medical centers were recoded into random letters
Table 6 Number of IVF treatments and success rate, by year
(2013-2014) and medical center (only medical centers
with ≥100 cycles per given year were included)





2013 Total 8,455 1,386 16.4
A 809 123 15.2
B 250 29 11.6
C 448 94 21.0
D 1,851 347 18.7
E 3,262 505 15.5
F 231 40 17.3
G 105 21 20.0
H 291 53 18.2
I 156 27 17.3
J 290 40 13.8
K 184 21 11.4
L 149 22 14.8
2014 Total 8,623 1,238 14.4
A 1,136 176 15.5
B 268 27 10.1
C 459 75 16.3
D 1,957 352 18.0
E 2,877 347 12.1
F 187 37 19.8
G 115 18 15.7
H 195 26 13.3
I 178 36 20.2
J 312 39 12.5
K 262 26 9.9
L 188 33 17.6
aMedical center: in order to protect the confidential information, the names of
the medical centers were recoded into random letters
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hundred and three treatments were performed in
women 44 years of age from 2011 to 2014, yielding 35
live births (1.6 %). (Table 4).
Live birth rate by medical center
Since outcome of a small number of treatments has
limited statistical significance, we decided to include
medical centers with >100 treatments per year in the
analysis. There are significant changes in success rate be-
tween medical centers, and significant changes within
the same medical center during the 4 years surveyed
(Tables 5 and 6).
Treatment distribution between public and private
medical centers
In 2007, 2,401 and 5,896 treatments were performed in
public and private medical centers, respectively. Treat-
ments in public medical centers increased marginally
from 2007 to 2014 (2,618 treatments in 2014, a 9 % in-
crease). Treatments in private medical centers increased
significantly from 2007 to 2014 (9,211 treatments in
2014, a 56 % increase) (Fig. 2).
Discussion and conclusions
In the current publication, we update a previous report
[8], and present an eight-year summary of IVF treatments
in Maccabi Healthcare Services. Since Maccabi covers ap-
proximately 25 % of the population in Israel, the data
herein reliably represent the total IVF activity in Israel.
We report a modest decrease in treatment cycles in recent
years. The Israeli success rate is low compared to inter-
national data (http://www.cdc.gov/art/reports/) [5, 6]. Of
note is a steady increase in patients’ mean age, and par-
ticularly, an increase in patients greater than 40 years old.
While both live birth per cycle and per patient show a
steady decline from 2007 through 2014, there is a marked
decrease in the number of cycles per patient from the
peak in 2011, suggesting possible changes in practice.
The health policy decisions that culminated in an un-
precedented coverage of IVF treatments in Israel reflect
societal and political considerations, as opposed to pure
professional, evidence-based considerations. Naturally,
these health policy decisions have a significant price tag.
Updated in 01-September-2015, according to the Minis-
try of Health, an IVF treatment reimbursement costs
12,000 NIS [10]. We report herein that 2,203 treatments
(26,436,000 NIS) were performed in women 44 years of
age from 2011 to 2014, yielding 35 live births. The cost
of a single live birth in that age group was 755,314 NIS
(not including fertility medications supplied by Maccabi).
Previous efforts of professional organizations (most
notably The Israel Fertility Association – IFA) to divert
resources in a more cost effective way (i.e. ovum donation)
have failed. Moreover, previous professionally based guide-
lines by the Ministry of Health itself to minimize futile
treatments were not implemented. Although in 1999, such
guidelines were adopted (http://www.ayala.org.il/?Cate
goryID=239&ArticleID=77) based on recommendations
made by a professional committee, nominated by the Min-
ister of Health, the guidelines are not currently imple-
mented. Moreover, a timely update was not published.
Given current IVF health policy, the practice of IVF
shifted from a medical treatment bearing indications and
contra-indications, into a social, age-related right [11].
This shift was fully endorsed by the legal system [12].
Economic costs of IVF treatments have a significant
impact on the Israeli HMO’s finances. A survey con-
ducted in Maccabi in 2006 found that 5.4 % of health
Fig. 2 IVF Treatments distribution between public and private medical centers, by year for 2007-2014
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expenditures for women related to fertility treatments,
more than was spent on diabetes (3.5 %) and comparable
to expenditures on cardiovascular diseases (5.9 %) [13].
Naturally, IVF health policy raises significant ethical
considerations. The Israel Fertility Association ethical
committee published its position regarding futile IVF
treatments in February 2015 [14]. The committee de-
fined a “futile treatment” as a treatment in which the
chance for live birth is <1 %, and strongly denounced
performing such treatment. Yet, experience shows that
these considerations are defeated when challenged.
In the current publication, we detail the live birth rate
achieved in different medical centers. These data must
be interpreted with caution given the lack of pertinent
individual clinical information i.e. indications, number of
oocytes retrieved, number of embryos obtained and their
quality, previous IVF failures, usage of specific technolo-
gies (pre-implantation genetic diagnosis, testicular sperm
extraction, in-vitro maturation etc.). We speculate that
units differ significantly as to their patients’ treatment
prognosis. In addition, some units impose a 44-age limit,
though, as mentioned above, the IVF national health
basket covers women until 45 years of age. Notably, the
number of treatments performed in “Clalit” public med-
ical centers is low; therefore, these units are under-
represented in our data.
According to the Ministry of Health, 39,174 IVF cycles
were performed in 2013 [7], with a live birth rate of
15.7 % (comparable to our data of 16.4 % for that year).
According to the CDC (http://www.cdc.gov/art/reports/)
163,212 cycles were performed in the US in the same
year with a live birth rate of 33 %. In our opinion, this
comparison highlights the fundamental problem that
erodes IVF clinical outcomes in Israel: Too many cycles
are performed despite a very slim chance of success.
IVF health-related policy is a subject of public and pro-
fessional debate, in which the question of resource alloca-
tion should be thoroughly and openly discussed. As
pointed out previously [15], the existing policy of assisted
reproduction in Israel, that is, of unlimited rounds with
IVF, should be further questioned and assessed. Possible
conclusions of such an assessment may be that IVF treat-
ments should cease before 45 years of age, and/or limiting
treatment number for an individual patient.
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